App-Quantinova.ai

Alpha fetoprotein (AFP) response and efficacy outcomes in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).

Robin Kate Kelley - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).

Munjid Al Harthy - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic castration-resistant prostate cancer

Cabozantinib

Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).

Zishuo Hu - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Cabozantinib

CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.

Funda Meric-Bernstam - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Cabozantinib

Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).

Ignacio Duran - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Cabozantinib

Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.

Gregory Russell Pond - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

A phase II study of cabozantinib as first-line treatment in metastatic collecting ducts carcinoma: The BONSAI trial.

Giuseppe Procopio - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cabozantinib

Sites of metastasis (mets) and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).

Dylan J Martini - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Cabozantinib

Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.

Molika Emmeline Keeler - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Cabozantinib

Association of inflammation and clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).

Dylan J Martini - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Cabozantinib

Body mass index (BMI) and toxicities and association with clinical outcomes (CO) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with cabozantinib (cabo).

Dylan J Martini - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Cabozantinib

Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.

Rosa Maria Nadal - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Analysis of toxicity and clinical outcomes (CO) in full versus reduced dose cabozantinib (cabo) in metastatic renal cell carcinoma (mRCC) patients (pts).

Dylan J Martini - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Cabozantinib

A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.

Stephanie Lheureux - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.

Wim van Boxtel - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.

Toni K. Choueiri - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).

Scot Anthony Niglio - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.

Neeraj Agarwal - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Cabozantinib

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Tian Zhang - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.

Joel W. Neal - American Society of Clinical Oncology (ASCO) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Filters

366 Abstracts